Autoimmune hepatitis in human immunodeficiency virus-infected patients: A case series and review of the literature

Table 3 Treatment and outcome of autoimmune hepatitis in human immunodeficiency virus-infected patients

	Induction regimen		Time to ALT normalization (mo)	Maintenance regimen		Outcome	Follow up duration (mo)	Last CD4 count	Last HIV VL (copies/mL)
	Prednisolone (mg/d)	Azathioprine (mg/d)		Prednisolone (mg/d)	Azathioprine (mg/d)
1	30	0	9.5	5	50	Minor flare	43.4	775	< 40
2	20	0	7.6	15	100	No relapse	12.8	799	< 40
3	30	0	8.2	0	50	No relapse	35.4	451	< 40
41	-	-	-	-	-	-	-	-	-
5	40	0	1.0	2.5	0	No relapse	10.3	772	< 40
6	30	0	2.6	10	100	No relapse	5.4	1841	< 40
7	15	25	0.9	0	MMF 1000 mg/day	No relapse	30.2	444	< 40
8	30	50	2.3	0	50	No relapse	65.8	513	< 40
9*	-	-	-	-	-	-	-	-	-
10	20	0	1.4	0	50	No relapse	22.6	632	< 40
11	30	0	7.6	0	50	No relapse	24.9	630	< 40
12	20	0	3.0	5	75	No relapse	19.7	176	< 40
13	30	0	Remain in the induction phase			-	4.9	-		-

¹Patients were initiated treatment at their primary hospitals. MMF: Mycophenolate mofetil.